Efocipegtrutide
Medium EvidenceEfocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching.
What It Is
Efocipegtrutide (HM15211) is an investigational, once-weekly, subcutaneously injected triple receptor agonist that simultaneously activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is developed by South Korea's Hanmi Pharmaceutical, which brands the molecule a 'LAPSTriple Agonist.' Structurally it is a chemical conjugate of a chimeric peptide (TA15211) engineered to hit all three receptors, linked to a human immunoglobulin G4 (IgG4) Fc fragment through Hanmi's proprietary LAPSCovery (Long-Acting Protein/Peptide Discovery) technology. The Fc partner acts as a molecular carrier that engages the neonatal Fc receptor (FcRn) recycling pathway, protecting the peptide from clearance and dramatically extending its in-vivo half-life so it can be dosed once weekly. Unlike the obesity-first triple agonist retatrutide, efocipegtrutide is being positioned principally as a liver-disease drug for MASH (metabolic dysfunction-associated steatohepatitis, previously NASH) and cholestatic/fibrotic conditions. The mechanistic logic of adding glucagon to the incretin backbone is threefold: GLP-1 activation suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion; GIP activation adds insulinotropic effect and is thought to improve tolerability; and glucagon activation raises energy expenditure and acts directly on hepatocytes to promote lipolysis and reduce hepatic fat, while also contributing anti-inflammatory and anti-fibrotic effects in the liver. Preclinical work from Hanmi (presented at EASL and AASLD) indicates that the glucagon component is essential to the direct anti-inflammatory and anti-fibrotic activity seen in chemically induced (TAA/CCl4) mouse models of liver injury, distinguishing a triple agonist from GLP-1-only or GLP-1/GIP agents whose liver benefit is largely secondary to weight loss. Clinically, a Phase 1b/2a randomized, double-blind, placebo-controlled study in obese subjects with non-alcoholic fatty liver disease showed dose-dependent reductions in liver fat content (MRI-PDFF) of approximately 19.6% (lowest dose) to 59.3% (highest dose) at week 12, versus roughly 5.7% with placebo, alongside body-weight reductions. Efocipegtrutide holds U.S. FDA Fast Track designation for MASH (granted 2020) and orphan-drug designations from both the FDA and EMA for PBC, PSC, and IPF. The current pivotal program is HM-TRIA-201 (NCT04505436), a Phase 2, adaptive, randomized, double-blind, placebo-controlled, multicenter, 52-week study in patients with biopsy-confirmed MASH and fibrosis conducted in the U.S. and Korea; its Independent Data Monitoring Committee has recommended the trial continue without modification. Efocipegtrutide is an investigational, manufacturer-developed biologic studied only in regulated clinical trials - it is not an approved medicine and not a self-sourced 'research peptide.'
Regulatory Status
Investigational (not approved by any regulator). FDA Fast Track for MASH; FDA and EMA orphan-drug designations for PBC, PSC, and IPF. No marketing application yet.
Why Researchers Study It
Efocipegtrutide is a leading test of whether adding glucagon-receptor agonism to the GLP-1/GIP incretin backbone can deliver liver-directed benefit in MASH that goes beyond what weight loss alone achieves - reducing steatosis, inflammation, and fibrosis through direct hepatic and energy-expenditure mechanisms. Its MASH-first (rather than obesity-first) positioning, its Fc-fusion long-acting design, and its orphan-designated potential in cholestatic/fibrotic diseases (PBC, PSC, IPF) make it a distinct data point in the crowded incretin field.
Proposed Mechanisms
- GLP-1 receptor agonism: enhances glucose-dependent insulin secretion, suppresses glucagon after meals, slows gastric emptying, and reduces appetite and food intake via central and peripheral pathways.
- GIP receptor agonism: provides additional insulinotropic effect and is thought to improve the metabolic and tolerability profile of the combined agonist.
- Glucagon receptor agonism: increases energy expenditure and acts directly on hepatocytes to stimulate lipolysis and reduce hepatic fat, contributing anti-steatotic, anti-inflammatory, and anti-fibrotic effects in preclinical liver-injury models.
- Balanced tri-agonism: the chimeric TA15211 peptide is tuned so glucagon-driven catabolic/hepatic effects complement GLP-1/GIP glycemic and appetite effects without provoking hyperglycemia.
- FcRn-mediated half-life extension (LAPSCovery): fusion to an IgG4 Fc fragment engages neonatal Fc receptor recycling, slowing clearance and enabling once-weekly subcutaneous dosing.
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| RCT (human, Phase 1b/2a) | Obese subjects with non-alcoholic fatty liver disease; once-weekly subcutaneous HM15211 (dose range up to 0.06 mg/kg) vs placebo over 12 weeks | Dose-dependent reduction in liver fat (MRI-PDFF) of ~19.6% (lowest dose) to ~59.3% (highest dose) at week 12 vs ~5.7% with placebo; accompanied by body-weight reduction; generally tolerable | Source |
| RCT (human, Phase 2 - HM-TRIA-201, ongoing) | Patients with biopsy-confirmed MASH and fibrosis; adaptive, randomized, double-blind, placebo-controlled, multicenter, 52-week study (US and Korea); NCT04505436 | Pivotal Phase 2 designed to assess histologic MASH resolution and fibrosis improvement; Independent Data Monitoring Committee recommended continuing the trial without modification | Source |
| Preclinical / mechanistic | TAA- and CCl4-induced mouse models of liver inflammation and fibrosis; comparison of triple agonism with removal of glucagon activity | HM15211 produced anti-inflammatory and anti-fibrotic effects; glucagon-receptor engagement was essential for the direct anti-inflammation/anti-fibrosis benefit, distinguishing it from GLP-1/GIP-only agents (EASL/AASLD posters) | Source |
| Regulatory milestone | FDA and EMA designation decisions for HM15211 | FDA Fast Track designation for MASH (2020); FDA and EMA orphan-drug designations for primary biliary cholangitis, primary sclerosing cholangitis, and idiopathic pulmonary fibrosis | Source |
Commonly Discussed Benefits
Researching Efocipegtrutide? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Investigational and not approved: efocipegtrutide is in Phase 2 development and is not available by prescription; its efficacy and safety in MASH remain to be confirmed in ongoing and future trials.
- No self-sourcing: HM15211 is a proprietary Hanmi biologic (a peptide-Fc conjugate) studied only in controlled trials. Material sold online as 'efocipegtrutide' or 'HM15211' is not the clinical drug and cannot be assumed authentic, pure, or safe.
- Gastrointestinal effects: as a GLP-1/GIP/glucagon agonist it is expected to cause nausea, vomiting, and diarrhea, usually mild-to-moderate and dose-dependent during titration.
- Glucagon-related effects: glucagon-receptor activation can raise glucose and heart rate and increase energy expenditure; balancing these against the incretin components is a key safety question for triple agonists and requires monitoring.
- Liver-endpoint uncertainty: promising liver-fat (MRI-PDFF) reductions are a surrogate; histologic MASH resolution and fibrosis improvement in the 52-week Phase 2 (and any Phase 3) are what establish clinical benefit.
- Early-stage evidence: much supporting data are preclinical or Phase 1b/2a and, in some cases, conference posters rather than full peer-reviewed publications; conclusions should be treated as preliminary.
Comparisons
See how Efocipegtrutide compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Efocipegtrutide (HM15211) pipeline overview - Hanmi Pharmaceutical PubMed
- [2] Study to Evaluate Efficacy, Safety and Tolerability of HM15211 (Efocipegtrutide) - HM-TRIA-201 (ClinicalTrials.gov NCT04505436) PubMed
- [3] A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in biopsy-confirmed NASH - design and rationale (HM-TRIA-201) PubMed
- [4] Hanmi Pharm's efocipegtrutide Phase 2 MASH trial gets green light from IDMC (Korea Biomedical Review) PubMed
- [5] Hanmi showcases efocipegtrutide's potential for liver fibrosis at AASLD (Korea Biomedical Review) PubMed
- [6] HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with NAFLD (Phase 1b/2a) PubMed
- [7] Next generation dual and triple GLP-1/GIP/glucagon agonists: a literature review (Nutr Metab Cardiovasc Dis) PubMed
Keep researching in the app
- Log Efocipegtrutide to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Retatrutide
High EvidenceAn investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.
Survodutide
Medium EvidenceA dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026.
Mazdutide
High EvidenceThe first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide.
Pemvidutide
Medium EvidenceA GLP-1/glucagon dual receptor agonist with FDA Breakthrough Therapy Designation for MASH, showing strong weight loss and liver benefits in Phase 2 trials.
Pegozafermin
Low EvidencePegozafermin (development code BIO89-100) is an investigational, long-acting analog of fibroblast growth factor 21 (FGF21) being developed for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and for severe hypertriglyceridemia (SHTG). Originally developed by 89bio and acquired by Roche in a deal announced in September 2025 (about $2.4 billion upfront and up to roughly $3.5 billion including a contingent value right), it uses site-specific glycoPEGylation to extend the very short half-life of native FGF21 to roughly 55-100 hours, enabling once-weekly or once-every-two-weeks subcutaneous dosing. FGF21 is a metabolic hormone that acts on liver, fat, and other tissues to improve insulin sensitivity, lower triglycerides, and exert direct anti-fibrotic and anti-inflammatory effects. In the Phase 2b ENLIVEN trial in biopsy-confirmed F2-F3 MASH, the 44 mg every-two-weeks dose produced at least a one-stage fibrosis improvement without worsening of MASH in about 27% of patients versus 7% on placebo, and MASH resolution without worsening of fibrosis in about 26% versus 2% on placebo, with benefits sustained through week 48. Pegozafermin holds FDA Breakthrough Therapy designation and EMA PRIME status for MASH and has advanced into the Phase 3 ENLIGHTEN program (ENLIGHTEN-Fibrosis in non-cirrhotic F2-F3 MASH and ENLIGHTEN-Cirrhosis in compensated F4 cirrhosis), plus the Phase 3 ENTRUST trial in SHTG.
Efruxifermin
Low EvidenceEfruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026).
Efinopegdutide
Medium EvidenceEfinopegdutide (MK-6024, formerly HM12525A and JNJ-64565111) is an investigational once-weekly subcutaneous dual agonist of the GLP-1 and glucagon receptors being developed by Merck for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and steatotic liver disease. It is a synthetic oxyntomodulin-based peptide - a modified GLP-1/glucagon dual-agonist sequence conjugated to a human IgG4 Fc fragment through a 10 kDa polyethylene glycol linker using Hanmi Pharmaceutical's LAPSCovery half-life-extension platform, which stretches dosing to once weekly. The design pairs the GLP-1 arm (appetite suppression, glycemic control, weight loss) with a glucagon arm that raises energy expenditure and acts directly on the liver to burn hepatic fat - the feature that sets it apart from pure GLP-1 drugs. In the head-to-head Phase 2a trial in NAFLD (Journal of Hepatology, 2023), efinopegdutide 10 mg cut liver fat content by 72.7% at 24 weeks versus 42.3% for semaglutide 1 mg, with two-thirds of efinopegdutide recipients falling below the 5% liver-fat threshold that defines a normal liver. Merck holds FDA Fast Track designation for the MASH program and is running Phase 2b studies plus a dedicated trial in compensated cirrhosis due to steatohepatitis; the earlier type 2 diabetes and obesity indications were discontinued in favor of the liver focus.